Pazopanib for the treatment of breast cancer. [Review]

MedStar author(s):
Citation: Expert Opinion on Investigational Drugs. 21(2):217-25, 2012 Feb.PMID: 22233389Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | ReviewSubject headings: *Angiogenesis Inhibitors/tu [Therapeutic Use] | *Breast Neoplasms/dt [Drug Therapy] | *Protein Kinase Inhibitors/tu [Therapeutic Use] | *Pyrimidines/tu [Therapeutic Use] | *Sulfonamides/tu [Therapeutic Use] | Breast Neoplasms/ge [Genetics] | Female | Humans | Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors] | Tumor Markers, BiologicalYear: 2012ISSN:
  • 1354-3784
Name of journal: Expert opinion on investigational drugsAbstract: INTRODUCTION: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.All authors: Amiri-Kordestani L, Swain SM, Tan ARFiscal year: FY2012Digital Object Identifier: Date added to catalog: 2013-09-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 22233389 Available 22233389

INTRODUCTION: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.

English

Powered by Koha